Close Menu

NEW YORK – Janssen Pharmaceutical said it submitted a biologics license application (BLA) to the US Food and Drug Administration on Thursday for amivantamab to treat non-small cell lung cancer patients with EGFR exon 20 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.